Comparison Of Differences In Recurrent Serum PSA Measurements With Reference Change Value
Öz
Objective: Prostate cancer is one of the most common cancers in men. The prostate-specific antigen is a biochemical parameter that is often used to diagnose and monitor prostate cancer. Since the intra-individual variability of the prostate-specific antigen is high, it is important to assess the significance of the change between two consequtive measurements from one individual. In our study, it was aimed to avoid unnecessary PSA requests by investigating whether the difference in recurrent serum PSA measurements exceeded Reference Change Value (RCV).
Material and method: PSA requests for a total of 4154
patients were retrospectively analyzed. A total of 268 individuals having
repeated test results with first PSA result ranging from 2-10 ng/mL were
selected. Analytical variability for total PSA was found as 5.1% and RCV was
calculated as 52%.
Results: While there was a decrease in serum PSA levels in 126
(47%) of the 268 patients who were included in the study, there was an increase
in 142 (53%). Among 142 patients whose PSA levels had increased in the second
measurement, 26 had increases exceeding the RCV. In our study, we found that
only 9.7% of patients with recurrent PSA requests had an increment above RCV.
Conclusion: When the increase in PSA values is evaluated, it
should be checked if it exceeds the RCV value and interpreted accordingly. The
significance of these elevations is controversial since most of the increment
percent in PSA observed in our study did not exceed RCV.
Anahtar Kelimeler
Kaynakça
- Referans1 American Cancer Society. Cancer Facts & Figures 2015. Cancer Facts Fig 2015;2015:1–9.
- Referans2 Graves HCB, Ph D. Standardization of lmmunoassays for Prostate-Specific Antigen A Problem of Prostate-Specific Antigen Complexation or a Problem of Assay Design:3141–4.
- Referans3 Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem. 1991;37:1618–25.
- Referans4 Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate [Internet]. 1981;2:89–96.
- Referans5 Atan A, Guzel O. How should prostate specific antigen be interpreted? Türk Üroloji Dergisi/Turkish J Urol [Internet] 2014;39:188–93.
- Referans6 Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate Specific Antigen Best Practice Statement: 2009 Update. J Urol [Internet]. Elsevier Inc 2009;182:2232–41.
- Referans7 Kutlu O, Koksal IT. Efforts for Improving the Efficiency of PSA: PSA Density, PSA Velocity, Age-specific PSA, and Free and Complexed PSA. Türk Üroloji Semin Urol Semin [Internet] 2013;3:55–60.
- Referans8 Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: any successor in sight. Rev Urol [Internet]. 2013;15:97–107.
Ayrıntılar
Birincil Dil
Türkçe
Konular
-
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
26 Mayıs 2017
Gönderilme Tarihi
28 Aralık 2016
Kabul Tarihi
11 Ocak 2017
Yayımlandığı Sayı
Yıl 2017 Cilt: 31 Sayı: 1